146 related articles for article (PubMed ID: 34184610)
1. Risk of hepatitis B virus reactivation following ruxolitinib treatment in patients with myeloproliferative neoplasms.
Duan MH; Cao XX; Chang L; Zhou DB
Hematology; 2021 Dec; 26(1):460-464. PubMed ID: 34184610
[TBL] [Abstract][Full Text] [Related]
2. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
Duan M; Zhou D
Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
[No Abstract] [Full Text] [Related]
3. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
4. Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis.
Cheung CKM; Law MF; Chao DC; Wong SH; Ho R; Chao ACW; Lai JWY; Chan TYT; Tam MTK; Lau SLF; Tam THC
J Dig Dis; 2020 Mar; 21(3):160-169. PubMed ID: 32040243
[TBL] [Abstract][Full Text] [Related]
5. Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.
Li P; Zhou L; Ye S; Zhang W; Wang J; Tang X; Liu J; Xu Y; Qian W; Liang A
Front Immunol; 2021; 12():638678. PubMed ID: 34335561
[TBL] [Abstract][Full Text] [Related]
6. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital.
Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
Arthritis Res Ther; 2019 Nov; 21(1):255. PubMed ID: 31779676
[TBL] [Abstract][Full Text] [Related]
7. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus reactivation in kidney transplant patients with resolved hepatitis B virus infection: Risk factors and the safety and efficacy of preemptive therapy.
Mei T; Noguchi H; Hisadome Y; Kaku K; Nishiki T; Okabe Y; Nakamura M
Transpl Infect Dis; 2020 Apr; 22(2):e13234. PubMed ID: 31856328
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma.
Liu WP; Wang XP; Zheng W; Ping LY; Zhang C; Wang GQ; Song YQ; Zhu J
Leuk Lymphoma; 2016; 57(6):1355-62. PubMed ID: 26727044
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation.
Fang J; Li W; Tan M; Chen W; Zhang C; Wang W; Xu Q; Guo X
Int Urol Nephrol; 2018 Sep; 50(9):1653-1660. PubMed ID: 29644524
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice.
Mo YQ; Liang AQ; Ma JD; Chen LF; Zheng DH; Schumacher HR; Dai L
BMC Musculoskelet Disord; 2014 Dec; 15():449. PubMed ID: 25532827
[TBL] [Abstract][Full Text] [Related]
12. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature.
Snast I; Atzmony L; Braun M; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Jul; 77(1):88-97.e5. PubMed ID: 28495497
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.
Zhang X; Zhou Y; Chen C; Fang W; Cai X; Zhang X; Zhao M; Zhang B; Jiang W; Lin Z; Ma Y; Yang Y; Huang Y; Zhao H; Xu R; Hong S; Zhang L
J Immunother Cancer; 2019 Nov; 7(1):322. PubMed ID: 31753012
[TBL] [Abstract][Full Text] [Related]
14. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis.
Paul S; Saxena A; Terrin N; Viveiros K; Balk EM; Wong JB
Ann Intern Med; 2016 Jan; 164(1):30-40. PubMed ID: 26595058
[TBL] [Abstract][Full Text] [Related]
16. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
17. Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment.
Gill H; Leung GMK; Seto WK; Kwong YL
Ann Hematol; 2019 Jan; 98(1):215-218. PubMed ID: 29946910
[No Abstract] [Full Text] [Related]
18. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K
Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study.
Jun BG; Kim YD; Kim SG; Kim YS; Jeong SW; Jang JY; Lee SH; Kim HS; Kang SH; Kim MY; Baik SK; Lee M; Kim TS; Choi DH; Choi SH; Suk KT; Kim DJ; Cheon GJ
PLoS One; 2018; 13(7):e0201316. PubMed ID: 30059513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
